Core Insights - MoonLake Immunotherapeutics is under investigation by Block & Leviton for potential securities law violations following a significant drop in share price after disappointing Phase 3 trial results [2][4]. Company Performance - Shares of MoonLake Immunotherapeutics fell over 85% in pre-market trading on September 29 due to the failure of one Phase 3 trial to meet its primary endpoint and modest gains in another trial compared to placebo [2]. - The Phase 3 data is considered to fall short of the previously touted Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2]. Legal Actions - Block & Leviton is investigating the public statements made by MoonLake regarding its drug trials and may file an action to recover losses for investors [4]. - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5]. Investor Eligibility - Any individual who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Whistleblower Information - Individuals with non-public information about MoonLake are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. CarMax reported disappointing financial results for Q2 2025 on September 25, 2025. The Company reported a 6.3% drop in comparable store used unit sales, and a decline in net earnings for the quarter. CarMax shares fell roughly 20% in response to its disappointing results. Accessibility StatementSkip Navigation If you are a shareholder who suffered ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements about the company's drug application process for MOLBREEVI BLA [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [3]. - Specific allegations include a lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, contradicting the company's public statements [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Insights - MoonLake Immunotherapeutics' shares dropped over 85% in pre-market trading on September 29 due to disappointing Phase 3 VELA trial results, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [2] - The Phase 3 data is considered inadequate compared to the previously reported Phase 2 MIRA trial results and is lagging behind competing drugs, raising concerns about the drug's commercial viability [2] - Block & Leviton is investigating potential securities law violations related to MoonLake's public statements about its drug trials [4] Company Overview - MoonLake Immunotherapeutics is a company involved in drug development, specifically in immunotherapeutics [2] - The company had previously highlighted positive results from its Phase 2 MIRA trial, which are now being overshadowed by the Phase 3 results [2] Legal Investigation - Block & Leviton is actively investigating whether MoonLake Immunotherapeutics committed securities law violations and may file actions to recover losses for affected investors [4] - Investors who have lost money on their MoonLake investments are encouraged to contact Block & Leviton for potential recovery options [5] Investor Eligibility - Any investor who purchased common stock of MoonLake Immunotherapeutics and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their shares [3] Whistleblower Information - Individuals with non-public information about MoonLake Immunotherapeutics are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, with potential rewards for original information [6]

Company Overview - Synopsys, Inc. is a technology company specializing in the design and verification of silicon chips for the semiconductor design and manufacturing industry [3]. Allegations and Financial Impact - On September 9, 2025, Synopsys reported missing its prior guidance on earnings per share and revenue for the third quarter of 2025, attributing the disappointing results to "new export restrictions" and disruptions with a major foundry customer [4]. - The company also cited "certain roadmap and resource decisions that did not yield their intended results" as contributing factors to the negative financial performance [4]. Stock Market Reaction - Following the announcement of the missed guidance, Synopsys' stock price fell by $216.59 per share, or 35.8%, closing at $387.78 per share on September 10, 2025 [5].

Core Insights - Block & Leviton LLP is investigating Barnes & Noble Education, Inc. for potential securities law violations following a significant drop in stock price due to accounting errors [1][2][5] Financial Reporting Issues - On July 21, 2025, Barnes & Noble's stock price fell over 20% after the company disclosed delays in filing its annual report, attributed to accounting errors [2] - An internal investigation indicated that the company may have overstated accounts receivable by up to $23 million, raising concerns about the accuracy of its financial reporting [2] - The company expects to identify at least one material weakness in internal controls, suggesting ineffective disclosure procedures for multiple fiscal years [2] Regulatory Filings - On September 12, 2025, Barnes & Noble announced a delay in filing its Form 10-Q for the period ending August 2, 2025, primarily due to the ongoing internal investigation [3] Investor Eligibility - Any investor who purchased Barnes & Noble Education, Inc. common stock and experienced a decline in share value may be eligible to seek recovery of losses [4] Legal Actions - Block & Leviton is actively investigating whether Barnes & Noble committed securities law violations and may file actions to recover losses for affected investors [5] Whistleblower Information - Individuals with non-public information about Barnes & Noble are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [7]

Core Viewpoint - Neogen Corporation (NASDAQ: NEOG) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its integration with the Food Safety Division of 3M Company, which misled investors about the progress of the integration [1]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from January 5, 2023, to June 3, 2025 [1]. - Defendants allegedly downplayed inefficiencies that arose during the integration process and assured investors of their commitment to resolving these issues quickly [1]. - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Flywire Corporation regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's revenue growth and business impacts from permit and visa restrictions [1][3]. Group 1: Allegations - The complaint alleges that during the class period from February 28, 2024, to February 25, 2025, Flywire's revenue growth was overstated [3]. - It is claimed that the negative impact of permit- and visa-related restrictions on Flywire's business was understated [3]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant time [3]. Group 2: Class Action Details - Shareholders who purchased shares of Flywire during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1][4]. - The deadline for shareholders to register for the class action is September 23, 2025 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and engage in good corporate citizenship [5].

Core Viewpoint - The Schall Law Firm is investigating claims against CTO Realty Growth, Inc. for potential violations of securities laws, particularly regarding misleading statements about the sustainability of its dividend [1][2]. Group 1: Investigation Details - The investigation centers on whether CTO Realty Growth issued false or misleading statements and failed to disclose important information to investors [2]. - A report by Wolfpack Research, published on June 25, 2025, alleges that CTO misled investors about its dividend sustainability, leading to a share price decline of over 5.4% [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who believe they have suffered losses due to the alleged misleading information from CTO [3].

Group 1 - Rowley Law PLLC is investigating potential securities law violations by Verint and its board of directors regarding the proposed acquisition by Thoma Bravo [1] - The acquisition deal values Verint at approximately $2 billion, with stockholders set to receive $20.50 for each share they hold [1] - The transaction is expected to close before the end of the fiscal year [1] Group 2 - Stockholders interested in the investigation can obtain additional information through Rowley Law PLLC's website or by contacting the firm directly [2] - Rowley Law PLLC represents shareholders in class actions and derivative lawsuits in complex corporate litigation [3]